Articles related to MENTAL HEALTH

With fast symptom relief and reinforcing effects, benzodiazepines were once the gold standard for treating insomnia and anxiety. As opioids dominate headlines along with the public health crisis of drug overdose deaths, is it time to reconsider benzodiazepines as a course of treatment?

To date, no Cdk5 inhibitor has been approved to treat any neuropsychiatric or degenerative diseases due to challenges at the blood-brain barrier. James Bibb, Ph.D., and colleagues seek to change that notion with their brain-permeable compound, 25-106.

A follow-up to the discussion we recently presented, this article asks doctors to look beyond the physical health of the patient to recognize and potentially treat muscle dysmorphia, the notion in which an individual is preoccupied with the idea that his or her body build is too small or insufficiently muscular.

The authors concluded that, after reviewing the 13-year-study, “switching to LAIs during the first 3 years of treatment improved antipsychotic adherence, decreased relapses, and reduced long-term mortality.” With few studies available comparing the long-term effectiveness between patients who switched to LAIs and those who remained on oral antipsychotics (OAPs), they hope the evidence presented supports the benefits of early LAI treatment in schizophrenia.

A video and transcript of a conversation between Harrison “Skip” Pope Jr., MD, MPH, of Harvard Medical School, and Katharine Phillips, MD, of New York-Presbyterian/Weill Cornell Medical Center, who discuss symptoms, treatments, and social propagation of “muscle dysmorphia”: a preoccupation with the belief that one’s body isn’t large or muscular enough.

Looking for some stimulating summer reading? From addiction to therapists to the psychopathy in charismatic leaders, these are books that can improve your understanding of yourself and others in your practice.